MedPath

A Phase II Study of Capecitabine plus Paclitaxel Combination Chemotherapy in Patients with Metastatic Breast Cancer

Phase 2
Conditions
Metastatic Breast Cancer
Registration Number
JPRN-UMIN000000869
Lead Sponsor
KBCSG (Kinki Breast Cancer Study Group)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Female
Target Recruitment
42
Inclusion Criteria

Not provided

Exclusion Criteria

1) Have Capecitabine before 2) Have Paclitaxel for metastatic lesion before 3) Hypersensitivity to drugs 4) active double cancer 5) severe complication 6) in pregnancy or lactation 7) Symptomatic brain metastasis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath